Argus Chemical Corporation v. Fibre Glass-Evercoat Company, Inc.

812 F.2d 1381, 1 U.S.P.Q. 2d (BNA) 1971, 1987 U.S. App. LEXIS 142
CourtCourt of Appeals for the Federal Circuit
DecidedFebruary 26, 1987
DocketAppeal 86-1449
StatusPublished
Cited by37 cases

This text of 812 F.2d 1381 (Argus Chemical Corporation v. Fibre Glass-Evercoat Company, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Argus Chemical Corporation v. Fibre Glass-Evercoat Company, Inc., 812 F.2d 1381, 1 U.S.P.Q. 2d (BNA) 1971, 1987 U.S. App. LEXIS 142 (Fed. Cir. 1987).

Opinion

FRIEDMAN, Circuit Judge.

This is an appeal from an order of the United States District Court for the Central District of California, dismissing an antitrust counterclaim to a suit for patent infringement and denying attorney’s fees. 645 F.Supp. 15, 230 USPQ 717 (1986). We affirm.

I

A. The appellee, Argus Chemical Corporation (Argus), in 1978 filed suit in the United States District Court for the Central District of California, charging the appellant, Fibre Glass-Evercoat Company, Inc. *1382 (Fibre Glass), with infringing two of its patents on homogeneous pigmented peroxide compositions. The two patents are known as the Pigmentation and the Homogeneous Patents. The compositions are used as a “hardener” for automobile body putty.

Claims of the patents involved in this case were limited to “wet” compositions of the product. As this court explained in the prior appeal in this case:

The claims of the Pigmentation Patent as originally written read equally well on both “dry” and “wet” compositions of the product. Upon confirming that sales had been made of dry pigmented benzoyl peroxide compositions prior to August 7,
1960, so as to constitute an “on sale” time bar under 35 U.S.C. § 102(b), the attorney handling the application amended the claims before initial examination, to avoid reading directly on any of the dry products sold, and, thereafter, all claims to dry compositions were dropped. The examiner was never informed of the sales of any dry composition.
Additional sales prior to the March 14, 1961, critical date were not disclosed in connection with the Homogeneous Patent.

759 F.2d 10, 12, 225 USPQ 1100, 1101, cert. denied, — U.S. —, 106 S.Ct. 231, 88 L.Ed.2d 230 (1985).

In defense, Fibre Glass challenged the validity of the patent and denied infringement. Fibre Glass also filed a counterclaim alleging that Argus had attempted to monopolize peroxide- and pigment-containing hardeners (paragraph 20) by, among other acts, seeking to enforce patents “known by plaintiff to be invalid” (paragraph 14), in violation of the antitrust laws.

After a bench trial, the district court held (1) that Fibre Glass had not shown that the patents were invalid, and (2) that Fibre Glass had infringed the patents. The court held that “there was no breach of an applicant’s duty of candor during examination under the standard of the early ’60’s by Argus’s failure to disclose the subject sales.” 759 F.2d at 12, 225 USPQ at 1102.

Although the court made detailed findings of fact and conclusions of law on the patent issues, its sole discussion of the antitrust counterclaim was contained in finding 45, which stated:

No basis has been found for defendant’s antitrust counterclaim resulting from acts after December 17, 1968 [the date on which the parties entered into mutual general releases (fdg. 44)], nor, for that matter, before that date.

B. On appeal, this court held that the patents were unenforceable because of Argus’ inequitable conduct before the Patent Office in failing to disclose the sales of the composition that had been made more than one year before the filing of the patent application. The court rejected Argus’ “good faith” defense:

Argus also attempts to avoid a holding of inequitable conduct by reason of the subjective “good faith” of its attorney, a defense applicable in common law fraud cases. It is Argus’s position that the precedent of this court is in error by failing to recognize that “fraud” is an intentional tort and that the “good faith” of the party charged is always a complete defense____
Contrary to Argus’s view, conduct before the PTO which may render a patent unenforceable is broader than the common law tort of fraud____
Counsel’s subjective “good faith” does not ... negate inequitable conduct. Rather, the question ... is whether a reasonable person in the position of Argus’s counsel knew or should have known that the information was material____
Because the withheld information on sales was clearly material, and Argus’s attorney should have known of its importance to the PTO’s consideration, inequitable conduct under the precedent of this court has been established.

759 F.2d at 14-15, 225 USPQ at 1103-04.

The court stated that, because of its holding that “the patents are unenforceable due to inequitable conduct, we do not need to address the other substantive issues of validity or infringement.” 759 F.2d *1383 at 15, 225 USPQ at 1104. The court did not refer to the antitrust counterclaim. It remanded the case for further proceedings in accordance with that opinion.

C. Following the remand, Argus moved for summary judgment on its antitrust counterclaim and for costs and attorney fees. The district court dismissed the counterclaim as “without merit.” It stated that Argus’ antitrust claims

speak in terms of fraud, bad faith, and/or specific intent. These issues are issues of fact, as to which this court has not made a finding.
Upon reviewing the evidence in this case, the court finds that the plaintiff pursued the patent process and the infringement litigation in the good faith belief that its claims were legitimate, that the failure to disclose the prior sales to the PTO was done in reliance upon what was then conceived to be the proper interpretation of the patent laws, and that there was no fraud involved in the patent process.
These findings are not inconsistent with the opinion of the appellate court, for although the court held the patents to be unenforceable, the ground therefore was specified to be “inequitable conduct before the patent and trademark office.” The court points out clearly that a holding of inequitable conduct is by no means equivalent to a holding of fraud or bad faith.

645 F.Supp. at 17, 230 USPQ at 719 (citations omitted).

The court also denied attorney fees. It stated that for a case to be “exceptional” under 35 U.S.C. § 285 (1982) — the basis for awarding attorney fees — “there must be proof of actual wrongful intent or gross negligence.” The court concluded:

In view of my findings that the plaintiff pursued this litigation in good faith belief that it had lawfully complied with all the rules of the patent office, and that its failure to make required disclosures to the patent office was the result of reliance upon an interpretation of the patent statutes believed at that time to be correct, I do not find this to be an exceptional case within the meaning of section 285.

645 F.Supp. at 18, 230 USPQ at 719.

II

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Caldera Pharmaceuticals, Inc. v. Regents of the University
205 Cal. App. 4th 338 (California Court of Appeal, 2012)
Metris U.S.A., Inc. v. Faro Technologies, Inc.
882 F. Supp. 2d 160 (D. Massachusetts, 2011)
Abbott Laboratories v. Teva Pharmaceuticals USA, Inc.
432 F. Supp. 2d 408 (D. Delaware, 2006)
Nisus Corp. v. Perma-Chink Systems, Inc.
421 F. Supp. 2d 1084 (E.D. Tennessee, 2006)
Molecular Diagnostics Laboratories v. Hoffmann-La Roche Inc.
402 F. Supp. 2d 276 (District of Columbia, 2005)
GFI, Inc. v. Bean Station Furniture
286 F. Supp. 2d 663 (M.D. North Carolina, 2003)
In Re Riser
298 B.R. 469 (M.D. Florida, 2003)
In Re Fry
271 B.R. 596 (C.D. Illinois, 2001)
Miller Pipeline Corp. v. British Gas PLC
69 F. Supp. 2d 1129 (S.D. Indiana, 1999)
Nobelpharma Ab v. Implant Innovations, Inc.
129 F.3d 1463 (Federal Circuit, 1998)
Baxa Corp. v. McGaw, Inc.
996 F. Supp. 1044 (D. Colorado, 1998)
Cabinet Vision and Larry Cornwell v. Cabnetware
129 F.3d 595 (Federal Circuit, 1997)
Boston Scientific Corp. v. Schneider (Europe) AG
983 F. Supp. 245 (D. Massachusetts, 1997)
Nobelpharma AB v. Implant Innovations, Inc.
930 F. Supp. 1241 (N.D. Illinois, 1996)
Santiago v. United States
884 F. Supp. 45 (D. Puerto Rico, 1995)
Ortho Diagnostic Systems, Inc. v. Miles Inc.
865 F. Supp. 1073 (S.D. New York, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
812 F.2d 1381, 1 U.S.P.Q. 2d (BNA) 1971, 1987 U.S. App. LEXIS 142, Counsel Stack Legal Research, https://law.counselstack.com/opinion/argus-chemical-corporation-v-fibre-glass-evercoat-company-inc-cafc-1987.